BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32816909)

  • 1. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
    Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 3. Cigarette smoke affects the onco-suppressor DAB2IP expression in bronchial epithelial cells of COPD patients.
    Anzalone G; Arcoleo G; Bucchieri F; Montalbano AM; Marchese R; Albano GD; Di Sano C; Moscato M; Gagliardo R; Ricciardolo FLM; Profita M
    Sci Rep; 2019 Oct; 9(1):15682. PubMed ID: 31666665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
    Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
    Zeng D; Liu M; Pan J
    Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
    Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
    Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
    [No Abstract]   [Full Text] [Related]  

  • 7. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
    Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
    Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
    Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
    Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
    Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
    Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.
    Huang B; Mu P; Yu Y; Zhu W; Jiang T; Deng R; Feng G; Wen J; Zhu X; Deng Y
    Gastric Cancer; 2021 Jan; 24(1):72-84. PubMed ID: 32529327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets.
    Milan TM; Eskenazi APE; Oliveira LD; Silva GD; Bighetti-Trevisan RL; Freitas GP; Almeida LO
    Cell Signal; 2023 Sep; 109():110773. PubMed ID: 37331417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments.
    Raghavan S; Mehta P; Xie Y; Lei YL; Mehta G
    J Immunother Cancer; 2019 Jul; 7(1):190. PubMed ID: 31324218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
    Chen Q; Zheng PS; Yang WT
    Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DAB2IP Expression in Abdominal Aortic Aneurysm: EZH2 and mir-363-3p as Potential Mediators.
    Legaki E; Klonaris C; Athanasiadis D; Patelis N; Sioziou A; Liakakos T; Gazouli M
    In Vivo; 2019; 33(3):737-742. PubMed ID: 31028191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
    Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.
    Fan X; Wang Y; Fan J; Chen R
    J Cell Biochem; 2019 Jun; 120(6):10643-10651. PubMed ID: 30672020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.
    Smits M; van Rijn S; Hulleman E; Biesmans D; van Vuurden DG; Kool M; Haberler C; Aronica E; Vandertop WP; Noske DP; Würdinger T
    Clin Cancer Res; 2012 Aug; 18(15):4048-58. PubMed ID: 22696229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.